Psychedelics for treatment resistant depression: are they game changers?

Psychedelic therapy is transforming treatment for treatment-resistant depression (TRD) by increasing benefits and reducing risks. Psilocybin shows promise as a potential game-changer, with initial evidence indicating a rapid antidepressant effect that lasts at least three months for some responders. However, more rigorous, double-blind, comparator-controlled trials with adequate statistical power are needed to understand how psychedelics work and their long-term effects in TRD. Psychedelics may also benefit other psychiatric conditions like bipolar depression and post-traumatic stress disorder.

Study at a glance

Abstract

Psychedelic therapy has created a paradigm shift in the treatment of TRD, as it can maximize therapeutic benefits and minimize potential risks. Psilocybin holds promise as a potential game-changer in the treatment of TRD, with initial evidence suggesting a rapid antidepressant effect sustained for some responders for at least 3 months. Nevertheless, further adequately powered, double-blind, comparator-controlled trials are required to explore and clarify the mechanisms of action and long-term effects of psychedelics in TRD. Psychedelics also hold promise for other psychiatric conditions, such as bipolar depression and post-traumatic stress disorder.